1. Clinical & Scientific Overview
Empagliflozin (TIP-MED-000052, Reference Code [4.8]) is classified under
Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04) as a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor (Gliflozin); Cardiorenal Protective Agent.
Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).
Jardiance (Boehringer Ingelheim), Gibtulio (Lupin)
Oral Film-Coated Tablets: 10 mg, 25 mg
3. Mechanism of Action & Pharmacodynamics
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor (Gliflozin); Cardiorenal Protective Agent acting on target receptor/enzyme pathways in Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04): clinical efficacy is mediated via Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor (Gliflozin); Cardiorenal Protective Agent for Type 2 diabetes mellitus (especially with established ASCVD or high CV risk); Chronic Heart Failure across the full ejection fraction spectrum (HFrEF and HFpEF—even in non-diabetics!); Chronic Kidney Disease (CKD) to slow eGFR decline and proteinuria progression..
4. Therapeutic Indications & Evidence-Supported Uses
- Type 2 diabetes mellitus (especially with established ASCVD or high CV risk)
- Chronic Heart Failure across the full ejection fraction spectrum (HFrEF and HFpEF—even in non-diabetics!)
- Chronic Kidney Disease (CKD) to slow eGFR decline and proteinuria progression
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: 10 mg once daily for Heart Failure, CKD, and Type 2 DM initiation; may increase to 25 mg once daily for additional glycaemic control in Type 2 DM if eGFR ≥45 mL/min. Follow physician prescription.
Administration & Meal Timing: With or without food (if FDC with metformin, take WITH breakfast). | Once daily in the morning (morning administration avoids osmotic nocturia at night).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Mechanism nuances by indication! • Glycaemic lowering effect diminishes when eGFR <45 mL/min. • Heart Failure & CKD cardiorenal protection persists down to eGFR ≥20 mL/min/1.73m2 (10 mg OD). Do not initiate if eGFR <20 mL/min or on dialysis. Note: An initial benign haemodynamic dip in eGFR of 3–5 mL/min within the first 2–4 weeks is expected due to reduced intraglomerular hyperfiltration and stabilises long-term. Hepatic: No dose adjustment in mild-to-moderate impairment; avoid in severe hepatic failure.
Renal: Mechanism nuances by indication! • Glycaemic lowering effect diminishes when eGFR <45 mL/min. • Heart Failure & CKD cardiorenal protection persists down to eGFR ≥20 mL/min/1.73m2 (10 mg OD). Do not initiate if eGFR <20 mL/min or on dialysis. Note: An initial benign haemodynamic dip in eGFR of 3–5 mL/min within the first 2–4 weeks is expected due to reduced intraglomerular hyperfiltration and stabilises long-term. Hepatic: No dose adjustment in mild-to-moderate impairment; avoid in severe hepatic failure.
Renal: Mechanism nuances by indication! • Glycaemic lowering effect diminishes when eGFR <45 mL/min. • Heart Failure & CKD cardiorenal protection persists down to eGFR ≥20 mL/min/1.73m2 (10 mg OD). Do not initiate if eGFR <20 mL/min or on dialysis. Note: An initial benign haemodynamic dip in eGFR of 3–5 mL/min within the first 2–4 weeks is expected due to reduced intraglomerular hyperfiltration and stabilises long-term. Hepatic: No dose adjustment in mild-to-moderate impairment; avoid in severe hepatic failure.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in Type 1 Diabetes (high risk of euglycaemic diabetic ketoacidosis — euDKA). Caution in elderly volume-depleted patients, recurrent genital/urinary infections, or active foot ulcers. MANDATORY PERIOPERATIVE & SICK-DAY HOLD: Withhold at least 3–4 days (72–96 hours) before any elective major surgery, colonoscopy/fasting procedure, or during acute febrile illness/gastroenteritis ('SAD-MANS'); check blood/urine ketones even if blood glucose is <200 mg/dL.
Key Clinical Precautions: Renal: Mechanism nuances by indication! • Glycaemic lowering effect diminishes when eGFR <45 mL/min. • Heart Failure & CKD cardiorenal protection persists down to eGFR ≥20 mL/min/1.73m2 (10 mg OD). Do not initiate if eGFR <20 mL/min or on dialysis. Note: An initial benign haemodynamic dip in eGFR of 3–5 mL/min within the first 2–4 weeks is expected due to reduced intraglomerular hyperfiltration and stabilises long-term. Hepatic: No dose adjustment in mild-to-moderate impairment; avoid in severe hepatic failure.
8. Adverse Effects Profile
- Genital mycotic (fungal) infections (vulvovaginal candidiasis in women, balanitis/balanoposthitis in uncircumcised men—5 to 10%), urinary tract infections, osmotic polyuria/increased urination, mild postural dizziness, modest weight loss (2–3 kg) and systolic BP reduction (3–5 mmHg).
- Euglycaemic Diabetic Ketoacidosis (euDKA—ketoacidosis occurring even when blood glucose is relatively normal or mildly elevated, <200–250 mg/dL!), Fournier's gangrene (rare necrotising fasciitis of the perineum—medical emergency), acute kidney injury from volume depletion, urosepsis.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Loop diuretics (furosemide, torsemide) increase risk of dehydration and orthostatic hypotension (diuretic dose often needs reduction when starting empagliflozin)
- Enhances hypoglycaemia if added to insulin or sulfonylureas without adjusting their dose (never abruptly stop insulin completely, as insulin deficiency triggers euDKA)
- Decreases serum lithium levels by increasing renal lithium excretion
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Mandatory Perineal Hygiene Counselling: Because empagliflozin removes excess sugar through the urine, sugar on the skin encourages fungal growth—instruct every male and female patient to wash the genital area with plain clean water after every urination and keep the area dry. Reassure non-diabetic heart failure or CKD patients that empagliflozin is prescribed to protect their heart and kidneys and will not drop normal blood sugar. Enforce the Sick Day / Pre-Surgery Hold Rule (pause during fasting, vomiting, or 3 days before surgery).
- Meal & Clock Timing Instruction: With or without food (if FDC with metformin, take WITH breakfast). (Once daily in the morning (morning administration avoids osmotic nocturia at night).)
- Missed Dose Protocol: Take as soon as remembered if before mid-afternoon; if evening, skip to avoid night-time urination.
- Geriatric Dispensing Pearl: Check volume status and blood pressure in elderly patients taking concurrent loop or thiazide diuretics to prevent dehydration and orthostatic falls. Warn elderly men with BPH or women with recurrent UTIs to report burning urination or genital itching early.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Film-Coated Tablets: 10 mg, 25 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 04 [4.8] (p. 48)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.